The Mexican vaccine, Patria, is still in phase 1 clinical studies; that is, it lags behind what was initially programmed, so the commitment to approve its emergency use by the end of 2021 cannot be met, as announced by the federal government.
In a recent government statement, it was reported that “the phase 1 clinical study began on May 20, 2021 and the three phases of human clinical studies are projected to conclude during the fourth quarter of 2021, to have the first mexican vaccine against covid-19 approved for emergency use by the end of 2021 ”.
However, personnel involved in vaccine development recognized MILLENNIUM that in September they will just announce the start of clinical phase 2 of the Homeland vaccine against SARS- CoV-2, designed with a recombinant Newcastle disease vector, proposed by the AVIMEX Laboratory.
One of the reasons was the start of the Roadrunner campaign and the presence of the third wave, especially the Delta variant, as well as the high incidence of sickness and mortality from covid.
For the development of said biological, the federal government “Granted a financing of 135.3 million pesos for conducting phase 1 and phase 2 clinical studies in humans ”.
The Federal Commission for the Protection Against Sanitary Risks (Cofepris) and the Ministry of Health are involved in the project, as well as the National Council of Science and Technology (Conacyt) assisted in the pilot scaling of the Patria vaccine in strict adherence to the “Good Manufacturing Practices ”, as well as in the establishment of all the critical elements to take this development to its industrial scale.
On April 13, 2021, the director of Conacyt, María Elena Álvarez-Buylla reported that the first batches of the vaccine against covid-19 had already been produced to start the phase 1 clinical trial with 90 to 100 volunteers from Mexico City, healthy people between the ages of 18 and 55.
María Elena Álvarez-Buylla also presented the development phases of the vaccine: phase 1 would take place between April and May; phase 2 from June-July, and phase 3 between August and October 2021.
The protection consisted of submitting between November and December 2021, the biological before Cofepris for authorization of emergency use and, with this, obtaining “savings of up to 855 percent with respect to the acquisition of foreign vaccines” and recognized that in science “There is uncertainty, but we have very solid confidence for it to become a Mexican vaccine development “.
Scientists from national and international universities participate in the development, as well as the National Institutes of Public Health in Mexico and the Mexican Institute of Social Security (IMSS) for the clinical research part.
Four vaccine developments against covid 19 were identified in the country, one of them Patria. Adding to this initiative, three vaccine developments against covid-19 developed by the Autonomous University of San Luis Potosí (UASLP), UNAM and the Autonomous University of Nuevo León (UANL) were identified and financed with 6 million pesos. in its initial phases of technological maturity.
In the third government report, the vaccine candidate developed by UASLP researchers will be ready for its pilot escalation and to start the stage of preclinical studies in animals during the second half of 2021.
And an additional vaccine development proposed by researchers from the UNAM’s Institute for Biomedical Research was identified, which is ready to begin preclinical trials.
As part of the strategy to regain sovereignty in the production of vaccines and other biopharmaceuticals, the strategic articulation proposal was developed for the creation of the National Research Coordination on Emerging, Tropical and Infectious Diseases. We are working on specific scientific research projects against anti-salmonella.
In innovation, the federal government during the month of November 2020, the ministering of 10 projects was carried out for an amount of 380 million pesos, and by June 2021 they are under development. With these strategic supports, scientific and technological capacities are promoted aimed at contributing to the national well-being and independence in medical devices for the care of cardiovascular diseases, anticancer drugs; and the creation and strengthening of two National Laboratories.
LG
– .
